Aurora delivers its first medical marijuana crop in Germany

Canadian producer Aurora Cannabis has delivered its first flower product in Germany’s growing medical marijuana market.

The Island Sweet Skunk sativa strain, which contains 20% THC, was produced under the Alberta-based company’s newly formed IndiMed brand, according to a news release.

“Aurora is proud to deliver to the rapidly growing German market our first domestically produced medical cannabis product – a significant step forward since Germany’s move to decriminalize cannabis earlier this year,” Aurora Europe President Michael Simon said in a statement.

The company’s European Union-Good Manufacturing Practice (GMP)-certified facility in Leuna, Germany, is one of only three licensed to cultivate marijuana in the country, he added.

Aurora is the latest Canadian cannabis operator to move into Germany after the European nation last year authorized “quasi legalization” of adult use and opened up its medical marijuana market.

Earlier this month, Alberta-based cannabis retailer High Tide entered Germany’s MMJ market by acquiring a 51% stake in Purecan GmbH for 4.8 million euros ($4.9 million) in a cash-and-stock deal.

Last November, Aphria RX, a subsidiary of Ontario- and New York-based Tilray Brands, launched the first commercial MMJ flower grown at its facility in Neumünster, Germany.

That product was the first grown by Aphria RX under the MMJ cultivation license the company received in July under Germany’s Medicinal Cannabis Act (MedCanG).

In a related announcement, Aurora said it has launched an internship program at the Leuna cultivation site in a partnership with University of Applied Sciences Erfurt.

Aurora shares trade as ACB on the Nasdaq and Toronto Stock Exchange.